BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30572639)

  • 1. CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer.
    Ring A; Nguyen C; Smbatyan G; Tripathy D; Yu M; Press M; Kahn M; Lang JE
    Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30572639
    [No Abstract]   [Full Text] [Related]  

  • 2. BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β-catenin acetylation.
    Li S; Wu H; Huang X; Jian Y; Kong L; Xu H; Ouyang Y; Chen X; Wu G; Yu L; Wang X
    J Pathol; 2021 Jul; 254(3):265-278. PubMed ID: 33797754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/β-catenin pathway.
    Li Z; Yang HY; Zhang XL; Zhang X; Huang YZ; Dai XY; Shi L; Zhou GR; Wei JF; Ding Q
    J Exp Clin Cancer Res; 2022 May; 41(1):168. PubMed ID: 35524313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Nalbantoglu U; Sener EF; Nurdinov N; Tascı B; Taheri S; Özkul Y; Donmez-Altuntas H; Canatan H; Ozpolat B
    J Mol Med (Berl); 2019 Apr; 97(4):491-508. PubMed ID: 30729279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
    Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
    Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer.
    Dey P; Wang A; Ziegler Y; Kim SH; El-Ashry D; Katzenellenbogen JA; Katzenellenbogen BS
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 10. Cadherin 11 Inhibition Downregulates β-catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer.
    Satriyo PB; Bamodu OA; Chen JH; Aryandono T; Haryana SM; Yeh CT; Chao TY
    J Clin Med; 2019 Jan; 8(2):. PubMed ID: 30691241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
    Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
    Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1.
    Zanin R; Pegoraro S; Ros G; Ciani Y; Piazza S; Bossi F; Bulla R; Zennaro C; Tonon F; Lazarevic D; Stupka E; Sgarra R; Manfioletti G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):313. PubMed ID: 31311575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
    Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    Narrandes S; Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1.
    Yi J; Li H; Chu B; Kon N; Hu X; Hu J; Xiong Y; Kaniskan HU; Jin J; Gu W
    Cell Death Differ; 2023 Jul; 30(7):1799-1810. PubMed ID: 37291217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Cancer Stem Cells in Triple-Negative Breast Cancer.
    Park SY; Choi JH; Nam JS
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31324052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
    Chan KC; Chan LS; Ip JC; Lo C; Yip TT; Ngan RK; Wong RN; Lo KW; Ng WT; Lee AW; Tsao GS; Kahn M; Lung ML; Mak NK
    Sci Rep; 2015 Apr; 5():9979. PubMed ID: 25897700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.